Follow WOWNEWS 24x7 on:
Zydus Lifesciences Ltd. has officially completed its landmark block acquisition of Amplitude Surgical SA, a French leader in lower-limb orthopaedic technologies. The deal, finalized on July 29, 2025, marks Zydus’ most significant international expansion in the MedTech space and sets the stage for a full takeover of the Paris-listed company.
Key Developments from the Block Acquisition
Zydus acquired 85.6 percent of Amplitude Surgical’s share capital and voting rights
The acquisition was executed at €6.25 per share, totaling €256.8 million
The deal was structured through the purchase of shares from PAI Partners and two minority shareholders
All regulatory and contractual conditions were fulfilled prior to closing
This strategic move positions Zydus as a major player in the global orthopaedic surgical market, expanding its footprint beyond pharmaceuticals into high-value medical devices.
Strategic Intent and Future Roadmap
Simplified Tender Offer and Squeeze-Out Plans
Zydus will file a mandatory simplified tender offer on July 30, 2025, for the remaining shares of Amplitude Surgical
The offer will match the acquisition price of €6.25 per share
With commitments from seven minority shareholders representing 4.7 percent of capital, Zydus is poised to cross the 90 percent ownership threshold
Upon completion, Zydus intends to initiate a squeeze-out procedure to acquire full control
Leadership Continuity and Operational Stability
Olivier Jallabert will continue as CEO of Amplitude Surgical
As part of the transaction, Jallabert has reinvested in the company, reinforcing management alignment
Amplitude Surgical terminated its liquidity contract with Oddo BHF and Natixis effective July 28, 2025
Regulatory and Market Implications
The tender offer is subject to clearance by the French Financial Market Authority (AMF)
No additional regulatory approvals are required, streamlining the path to full acquisition
The offer is expected to open in September 2025, pending AMF approval
This acquisition is expected to be transformative for Zydus, enabling it to diversify revenue streams and leverage Amplitude’s innovation pipeline.
Financial and Strategic Impact
Amplitude Surgical reported revenue of nearly €111 million as of June 30, 2025
The company employs 429 people and operates in over 30 countries
Zydus’ acquisition provides access to proprietary technologies in hip and knee surgery
The deal aligns with Zydus’ broader strategy to build a global MedTech platform
Amplitude’s strong presence in Europe and its innovation-led approach make it a valuable asset for Zydus’ long-term growth ambitions.
Market Sentiment and Investor Takeaways
The acquisition signals Zydus’ intent to become a diversified healthcare conglomerate
Investors may view the move as a strategic hedge against pharma sector volatility
The transaction could unlock synergies in R&D, distribution, and regulatory pathways
Zydus’ shares are expected to reflect positive momentum as the company integrates Amplitude Surgical and prepares for the next phase of its MedTech journey.
Conclusion
Zydus Lifesciences’ completion of the Amplitude Surgical block acquisition marks a pivotal moment in its evolution from a pharmaceutical powerhouse to a global healthcare innovator. With a simplified tender offer on the horizon and full control within reach, Zydus is poised to redefine its role in the surgical technology space.
Source: BusinessWire – July 29, 2025 FinanzWire – July 29, 2025 Express Pharma – July 29, 2025 CNBC TV18 – July 29, 2025 Indian Pharma Post – July 29, 2025
Follow WOWNEWS 24x7 on:
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
